Table 7 Change in ICQ score at 6-months for increased ICS and decreased ICS dose groups

Total Score

8 (3–26)

16 (7–24)

16 (8–28)

11 (5–31)

0.460

Voice Problems

8 (2–25)^†

13 (4–37)

14 (6–36)

13 (2–22)^†

0.026

Oropharynx Problems

24 (7–39)

30 (11–42)

29 (12–38)

13 (6–33)

0.330

Unpleasant Taste

5 (0–25)

17 (4–29)

8 (0–20)

5 (0–24)

0.155

Skin, Hair and Nails

7 (0–27)

14 (1–33)

23 (13–31)

11 (4–36)

0.064

Mood Problems

6 (0–31)

0 (0–22)

3 (0–33)

0 (0–19)

0.455

Taste Disruption

0 (0–28)

6 (0–17)

0 (0–18)

0 (0–17)

0.379

Perspiration

17 (0–42)

17 (0–42)

17 (0–38)^†

17 (0–27)

0.109

Oropharyngeal Itching

0 (0–21)

0 (0–17)

0 (0–10)

0 (0–19)

0.533

Thirst

17 (0–50)^†

25 (0–42)

17 (0–29)

13 (0–42)

0.593

Tiredness

17 (0–46)

25 (0–33)

33 (0–52)

29 (0–52)

0.465

Oral Candidiasis

0 (0–17)

0 (0–17)

0 (0–33)

0 (0–17)

0.403

Facial Oedema

0 (0–0)

0 (0–17)

0 (0–17)

0 (0–0)

0.056

Vision Deterioration

0 (0–33)

0 (0–33)

0 (0–33)

0 (0–17)

0.756

Dental Deterioration

0 (0–0)

0 (0–17)^†

0 (0–17)

0 (0–0)^†

0.185

Eye Dryness

0 (0–17)

0 (0–17)

33 (0–50)

17 (0–50)

0.915